UBS Group’s Revelation Biosciences, Inc. Unit REVBU Stock Holding History

UBS Group’s Portfolio REVBU Stock Details REVBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-788	Closed	-$189	–	11504
2022 Q4	$189	Sell	788 -2,462	-76%	-$757	﹤0.01%	10326
2022 Q3	$1K	Buy	+3,250	New	+$2.24K	﹤0.01%	10215
2021 Q4	–	Sell	-167	Closed	-$2K	–	11083
2021 Q3	$2K	Sell	167 -100	-37%	-$1.06K	﹤0.01%	9062
2021 Q2	$3K	Sell	267 -999	-79%	-$10.5K	﹤0.01%	8878
2021 Q1	$13K	Sell	1,266 -8,175	-87%	-$90.9K	﹤0.01%	7764
2020 Q4	$102K	Buy	+9,441	New	+$95.8K	﹤0.01%	5676

UBS Group's REVBU Position: Q1 2023 in Review

UBS Group sold out of Revelation Biosciences, Inc. Unit (REVBU) in Q1 2023, closing a stake of 788 shares — an estimated $189 sold.

UBS Group first reported a position in REVBU in Q4 2020 and held it in 6 quarters. The position peaked at $102K in Q4 2020. 0 funds tracked by Wall St. Rank hold REVBU as of Q1 2023.

UBS Group reported no remaining Revelation Biosciences, Inc. Unit position as of Q1 2023 after selling out during the quarter.
UBS Group sold 788 Revelation Biosciences, Inc. Unit shares in Q1 2023, an estimated $189.
UBS Group first reported a position in Revelation Biosciences, Inc. Unit in Q4 2020 and held it in 6 quarters.
UBS Group's Revelation Biosciences, Inc. Unit position peaked at $102K in Q4 2020.
0 funds tracked by Wall St. Rank held Revelation Biosciences, Inc. Unit as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.